X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs SUN PHARMA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD SUN PHARMA STRIDES SHASUN LTD/
SUN PHARMA
 
P/E (TTM) x 13.6 24.0 56.5% View Chart
P/BV x 1.6 3.5 44.8% View Chart
Dividend Yield % 0.6 0.7 96.2%  

Financials

 STRIDES SHASUN LTD   SUN PHARMA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
SUN PHARMA
Mar-17
STRIDES SHASUN LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,275842 151.4%   
Low Rs918572 160.4%   
Sales per share (Unadj.) Rs389.6131.6 296.0%  
Earnings per share (Unadj.) Rs28.032.7 85.5%  
Cash flow per share (Unadj.) Rs48.938.0 128.8%  
Dividends per share (Unadj.) Rs4.503.50 128.6%  
Dividend yield (eoy) %0.40.5 82.9%  
Book value per share (Unadj.) Rs303.1152.7 198.5%  
Shares outstanding (eoy) m89.422,399.26 3.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.85.4 52.4%   
Avg P/E ratio x39.221.6 181.3%  
P/CF ratio (eoy) x22.418.6 120.4%  
Price / Book Value ratio x3.64.6 78.1%  
Dividend payout %16.110.7 150.3%   
Avg Mkt Cap Rs m98,0361,696,877 5.8%   
No. of employees `0005.817.5 33.1%   
Total wages/salary Rs m5,88149,023 12.0%   
Avg. sales/employee Rs Th6,005.918,028.3 33.3%   
Avg. wages/employee Rs Th1,014.02,798.8 36.2%   
Avg. net profit/employee Rs Th431.24,479.5 9.6%   
INCOME DATA
Net Sales Rs m34,834315,784 11.0%  
Other income Rs m1,6866,232 27.1%   
Total revenues Rs m36,520322,016 11.3%   
Gross profit Rs m6,428100,893 6.4%  
Depreciation Rs m1,87212,648 14.8%   
Interest Rs m2,2693,998 56.8%   
Profit before tax Rs m3,97390,479 4.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m499 3.6%   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m47012,116 3.9%   
Profit after tax Rs m2,50178,462 3.2%  
Gross profit margin %18.531.9 57.8%  
Effective tax rate %11.813.4 88.3%   
Net profit margin %7.224.8 28.9%  
BALANCE SHEET DATA
Current assets Rs m38,165329,537 11.6%   
Current liabilities Rs m30,402178,870 17.0%   
Net working cap to sales %22.347.7 46.7%  
Current ratio x1.31.8 68.1%  
Inventory Days Days7779 97.9%  
Debtors Days Days10483 125.5%  
Net fixed assets Rs m37,639204,766 18.4%   
Share capital Rs m8942,399 37.3%   
"Free" reserves Rs m26,210363,997 7.2%   
Net worth Rs m27,105366,397 7.4%   
Long term debt Rs m16,37714,361 114.0%   
Total assets Rs m81,168614,102 13.2%  
Interest coverage x2.823.6 11.6%   
Debt to equity ratio x0.60 1,541.6%  
Sales to assets ratio x0.40.5 83.5%   
Return on assets %5.913.4 43.8%  
Return on equity %9.221.4 43.1%  
Return on capital %12.124.8 48.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46544,118 30.5%   
Fx outflow Rs m4,07624,484 16.6%   
Net fx Rs m9,38919,634 47.8%   
CASH FLOW
From Operations Rs m2,88170,822 4.1%  
From Investments Rs m-7,051-42,216 16.7%  
From Financial Activity Rs m3,382-22,854 -14.8%  
Net Cashflow Rs m-7886,107 -12.9%  

Share Holding

Indian Promoters % 27.7 63.7 43.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 5.1 736.8%  
FIIs % 8.6 23.0 37.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 8.3 312.0%  
Shareholders   56,241 133,026 42.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and FMCG sector witnessing maximum buying interest.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Feb 21, 2018 12:41 PM

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - ALEMBIC PHARMA COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS